Zai Lab stock has rebounded sharply over the short term, yet its longer term share price record and current valuation checks point to a more cautious picture for investors trying to judge what the recent move really means.
- Over the past 5 years, Zai Lab has fallen about 84.5%, which leaves long term holders with a material drawdown even after the recent bounce.
- Regulatory progress such as Orphan Drug Designation for its DLL3-targeting therapy Zocilurtatug Pelitecan can support expectations for future cash flows. At the same time, execution risk across its expanding oncology and immunology pipeline may still weigh on how much value the market is willing to assign today.
- The stock currently scores 4 out of 6 on the broader valuation checks, which is a mixed picture rather than a clear bargain or clear overvaluation, as shown in this valuation summary.
The issue now is whether the recent strength in Zai Lab’s share price has simply closed a gap to fundamentals or gone beyond what its current valuation support justifies.
Find out why Zai Lab's -33.3% return over the last year is lagging behind its peers.
Has Zai Lab Run Too Far on Sales?
P/S is often a better fit for Zai Lab because the company is still reporting free cash flow losses, so sales provide a cleaner anchor for comparison. On this measure, Zai Lab trades on a P/S of 5.8x, which is below the biotech industry average of 11.4x and also below the peer group average of 7.5x.
The tailored fair P/S ratio for Zai Lab is 3.5x, which reflects its specific mix of growth prospects, margins, size and risk profile. That is a clear gap to the current 5.8x multiple, which indicates that investors are already paying a premium relative to what this framework would treat as reasonable for the stock. Despite the recent positive catalyst around Orphan Drug Designation for Zocilurtatug Pelitecan, the P/S still appears elevated compared with this fair value marker.
On this P/S yardstick, Zai Lab stock appears overvalued relative to what its fundamentals and risk profile would typically justify.
See what the numbers say about this price — find out in our valuation breakdown.
The Zai Lab Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Zai Lab are the link between the current valuation puzzle and the assumptions that would need to hold on future growth, margins and earnings for the stock to be worth materially more or less than it is today. They sit on the company’s Community page. Each Narrative sets out Zai Lab's implied fair value as a thesis about the business that you can revisit over time, rather than treating it as a static number.
One of the top community narratives on Zai Lab: roughly fairly valued
"This narrative explores a more pessimistic perspective on Zai Lab compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts…"
Read one of the top narratives on Zai Lab
Do you think there's more to the story for Zai Lab? Head over to our Community to see what others are saying!
The Bottom Line
For Zai Lab, the current signals point to a stock that screens as overvalued on P/S relative to its tailored fair multiple, even though the broader valuation checks are not outright weak. The market is already giving the company credit for meaningful future progress across its pipeline, while long term shareholders still sit on a large 5 year drawdown. The key question from here is whether Zai Lab can convert its clinical and regulatory milestones into enough durable revenue and margin improvement to justify that premium, or whether the stock will remain a potential value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com